Follow on Google News News By Tag * Healthcare * Regards * Ratings * Asia * Pharmaceuticals * Medicines * Q211 * Multinational * Pharmaceutical * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Recently released market study: Indonesia Pharmaceuticals & Healthcare Report Q3 2011New Healthcare research report from Business Monitor International is now available from Fast Market Research
Headline Expenditure Projections * Pharmaceuticals: * Healthcare: * Medical devices: IDR2,758bn (US$304mn) in 2010 to IDR3,081bn (US$350mn) in 2011; 11.7% growth in local currency terms and 15.3% in US dollar terms. Our forecast has been revised up moderately from Q211 due to macroeconomic factors. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Business Environment Rating: BMI's Pharmaceuticals & Healthcare BERs assess countries according to their risk/reward profile. In BMI's BER matrix for Q311, Indonesia occupies 12th place of the 17 regional markets surveyed in the Asia Pacific region. The country's pharmaceutical rating stands at 47.4, lower than the average for the region. The main drawbacks to investment in Indonesia include corruption, low per-capita spending on pharmaceuticals and a small proportion of the elderly in the country. On the other hand, factors such annual growth of its pharmaceutical market, coupled with rising population numbers and a relatively solid political and economic base are expected to encourage multinationals to invest in the country despite a risky operating environment. Key Trends And Developments * Merck KGaA's subsidiary in Indonesia, PT Merck Tbk reported revenues of IDR796bn (US$87.6mn) in 2010, a 5.9% growth (in local currency) from 2009 revenues of IDR751bn (US$72.7mn).The increase in sales was attributed mainly to the company's Merck Serono division which deals with prescription drugs, accounting for 41% of sales, followed by its customer health care division and chemical division accounting for 25% and 34% of the 2010 revenue. BMI Economic View: Indonesia's real GDP expanded by 6.9% year-on-year (y-o-y) in Q410, the fastest pace since 2004, led by robust growth in both private consumption and gross fixed capital formation (GFCF). Notably, this strong print was markedly above consensus (6.3% median estimate) and caps a stellar 2010 with overall growth of 6.1%. We remain bullish on the Indonesian economy in 2011 and 2012, forecasting real GDP to reach 5.9% and 6.0% respectively. However, we note that the outlook in the next few months will be clouded by rising consumer price pressures and the prospect of more rate hikes. BMI Political View: We believe a cabinet reshuffle is in order in the coming months as Indonesian President Susilo Bambang Yudhoyono seeks to account for his administration's failure to curb religious extremism and rein in corruption. We also highlight the possibility of a broader shakeup within the ruling coalition that may lead to the departure of Golkar party. Partial Table of Contents: SWOT Analysis - Indonesia Pharmaceutical And Healthcare Industry SWOT - Indonesia Political SWOT - Indonesia Economic SWOT - Indonesia Business Environment SWOT Pharmaceutical Business Environment Rating - Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q311 - Rewards - Risks Market Summary - Indonesia Regulatory Regime - Intellectual Property Issues - Generic Drug Legislation - Labelling Requirements - Counterfeit and Substandard Drugs - Free Trade Agreements - Pricing Regime - Reimbursement Regime Industry Trends and Developments - Epidemiology - Recent Public Health Developments - Table: UN Millennium Development Goals - Healthcare System - Healthcare System Reform - International Healthcare Collaborations - Pharmaceutical Retail Sector - Research and Development - Herbal Medicines - Medical Devices Industry Forecast Scenario - Overall Market Forecast - Table: Pharmaceutical Sales Indicators 2007-2015 - Key Growth Factors - Industry - Table: Healthcare Expenditure Indicators 2007-2015 - Table: Government Healthcare Expenditure Indicators 2007-2015 - Table: Private Healthcare Expenditure Indicators 2007-2015 - Key Growth Factors - Macroeconomic - Table: Indonesia - Economic Activity - Prescription Drug Market Forecast - Table: Prescription Drug Sales Indicators 2007-2015 - Patented Drug Market Forecast - Table: Patented Drug Market Indicators 2007-2015 - Generic Drug Market Forecast - Table: Generic Drug Sales Indicators 2007-2015 - OTC Medicine Market Forecast - Table: OTC Medicine Sales Indicators 2007-2015 - Medical Device Market Forecast - Table: Medical Devices Sales Indicators 2007-2015 - Pharmaceutical Trade Forecast - Table: Exports and Imports Indicators 2007-2015 - Other Healthcare Data and Forecasts - Key Risks to BMI's Forecast Scenario Competitive Landscape Company Profiles - PT Kalbe Farma - PT Bio Farma - Kimia Farma - Combiphar PT - Sanofi-Aventis - Pfizer - Novartis - GlaxoSmithKline (GSK) - Merck & Co - Bayer Country Snapshot: Indonesia Demographic Data - Section 1: Population - Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number